Back to Journals » Therapeutics and Clinical Risk Management » Volume 2 » Issue 3

Alendronate sodium in the management of osteoporosis

Authors P J J Prinsloo, DJ Hosking

Published 15 September 2006 Volume 2006:2(3) Pages 235—249

P J J Prinsloo1, D J Hosking2


1Dept of Clinical Chemistry, City Hospital, Nottingham, UK; 2Dept Endocrinology and Diabetes, City Hospital, Nottingham, UK

 

 

Abstract: Alendronate is one of the best and most extensively studied bisphosphonates in the treatment of osteoporosis. This review considers in detail the major pivotal study, the fracture intervention trial (FIT), upon which the use of alendronate is based and which was a landmark study in terms of design, size and clinical impact. The role of alendronate has subsequently been underscored by a range of studies extending the clinical indications for its use and consolidating the effect on reducing both vertebral and non-vertebral fracture risk. Although the emphasis of these studies has predominantly been on the management of postmenopausal osteoporosis, data is also available in primary prevention, men, and glucocorticoids-induced osteoporosis. Direct comparison between the different drugs used to treat osteoporosis with fracture end points are needed for patients and doctors to make informed choices, but the size of such studies are prohibitive. Clinical trials using surrogate markers such as bone mineral density and biochemical markers of bone turnover have been performed which provide some helpful information but the limitations of this approach need to be recognized.

 

 

Keywords: alendronate, osteoporosis, hormone replacement therapy, male osteoporosis, parathyroid hormone, corticosteroid-induced osteoporosis

Download Article [PDF] 

Readers of this article also read:

Fluoromica nanoparticle cytotoxicity in macrophages decreases with size and extent of uptake

Tee N, Zhu Y, Mortimer GM, Martin DJ, Minchin RF

International Journal of Nanomedicine 2015, 10:2363-2375

Published Date: 26 March 2015

Exemestane in early breast cancer: a review

Michael Untch, Christian Jackisch

Therapeutics and Clinical Risk Management 2008, 4:1295-1304

Published Date: 5 December 2008

Treatment of hereditary angioedema with plasma-derived C1 inhibitor

Michael J Prematta, Tracy Prematta, Timothy J Craig

Therapeutics and Clinical Risk Management 2008, 4:975-982

Published Date: 10 October 2008

Raltegravir: first in class HIV integrase inhibitor

Zelalem Temesgen, Dawd S Siraj

Therapeutics and Clinical Risk Management 2008, 4:493-500

Published Date: 11 April 2008

Update on local anesthetics: focus on levobupivacaine

Crina L Burlacu, Donal J Buggy

Therapeutics and Clinical Risk Management 2008, 4:381-392

Published Date: 11 April 2008

Update on the treatment of ankylosing spondylitis

Walter P Maksymowych

Therapeutics and Clinical Risk Management 2007, 3:1125-1133

Published Date: 15 January 2008

Editorial || FREE PAPER ||

Garry M Walsh

Therapeutics and Clinical Risk Management 2007, 3:361-362

Published Date: 15 July 2007

Editorial ||FREE PAPER||

Garry Walsh

Therapeutics and Clinical Risk Management 2006, 2:227-228

Published Date: 15 September 2006